Not satisfied with a 100,000+ user base, a recognizable 18-year-old brand, and a target market in excess of two billion Chinese speaking people, ChineseInvestors.com recently executed a first-to-market milestone by creating the world’s only Chinese language, cannabinoid-based, therapeutic health products online store, http://www.ChineseCBDoil.com.
ABcann is new to the public market, having launched its initial public offering on May 4. However, the company is one of the most experienced Canadian growers.
InMed Pharmaceuticals, Inc.’s (CSE: IN) (OTCQB: IMLFF) study, which generated an article published in the European Journal of Pain (http://nnw.fm/SVF1j), sets the stage for more research into how a topically-applied drug can provide relief of chronic or acute pain without central side effects, according to Dr. Sazzad Hossain, chief scientific officer of InMed.
India Globalization Capital, Inc. (NYSE MKT: IGC) is a first mover in developing a portfolio of products using cannabis-based “combination therapies” for the treatment of pain and other conditions.
This inhibition has been a major obstacle for dispensaries and other cannabis-related businesses, but the use of bitcoin technology could be the key to overcoming the roadblock.
Its drug development pipeline consists of treatments for seizures, neuropathic pain, and eating disorders, but one gaining attention is an experimental cannabis-based drug for Alzheimer’s disease, IGC-AD1.
On Monday, January 30, 2017, Alan Klitenic, the Director of Investor Relations for ChineseInvestors.com, Inc. (OTCQB: CIIX), was interviewed by NetworkNewsWire.
Cannabis has been used for thousands of years as a form of natural remedy. But, over time, the possession of marijuana was made illegal in many countries, until now.
Now, India Globalization Capital, Inc. (NYSE MKT: IGC) is taking a leaf from the Sony playbook. This pioneering company is a ‘first mover’ in the cannabinoid combination therapy space.
Before the opening bell, top-ranked independent research firm WallStreet Research™ (WSR) announced the release of a Corporate Profile Analyst Report covering ChineseInvestors.com, Inc. (OTCQB: CIIX).
PI has put a “Buy” rating on the stock and set a one-year price target of $2.25, implying a return of well over 100 percent.
CBD has long been considered to have a broad range of medical benefits. Now, two major studies released in the last four months have scientifically validated the medicinal efficacy of CBD.
ChineseInvestors.com, Inc. (OTCQB: CIIX), the premier financial information website for Chinese-speaking investors in both the U.S. and China, today announced that it has engaged the expertise of NetworkNewsWire (“NNW”), a multifaceted financial news and publishing company that delivers a new generation of social communication solutions, news aggregation and syndication, and enhanced news release services.
With so many medically beneficial applications, its little wonder that Algae Dynamics Corp. (OTC: ADYNF) has focused on commercialization of its proprietary BiloSilo™ system for the high volume, low cost production of contaminant-free algae biomass.
The Bethesda, Maryland-based company is a first mover in “combination therapies” that merge cannabinoids with existing drugs to provide more effective remedies.
